Company research
SCYNEXIS INC
CIK 1178253Updated Nov 17, 2026
SCYX price & chart
Loading TradingView…
NASDAQ:SCYX on TradingView ↗About the company
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’ proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical development as an oral and IV antifungal for the treatment and prevention of invasive fungal infections. For more information, visit www.scynexis.com.
In the news
SCYNEXIS to Participate in Upcoming Investor Conferences ↗
Recent filings
S-3 filing
10-Q filing
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
Show 5 more recent filings
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01
SCHEDULE 13G/A filing
SCHEDULE 13G/A - filed by GREAT POINT PARTNERS LLC regarding SCYNEXIS INC
SCHEDULE 13G - filed by Adage Capital Management, L.P. regarding SCYNEXIS INC
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 51,071,000Source | 99,038,000Source | 74,970,000Source | 60,694,000Source | 107,806,000Source | 77,626,000Source | 67,915,000Source | 118,254,000Source | 59,027,000Source | 90,643,000Source | 128,412,000Source | 87,810,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 0Source | 408,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 14,797,000Source | 28,730,000Source | 10,487,000Source | 11,020,000Source | 25,994,000Source | 36,671,000Source | 6,942,000Source | 35,482,000Source | 21,259,000Source | 16,051,000Source | 34,050,000Source | 45,814,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 2,101,000Source |
| Inventory, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 899,000Source |
| Assets, CurrentUSD | 48,694,000Source | 80,463,000Source | 56,236,000Source | 56,498,000Source | 94,578,000Source | 62,691,000Source | 52,221,000Source | 101,673,000Source | 40,374,000Source | 72,181,000Source | 102,116,000Source | 79,061,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 686,000Source | 1,538,000Source | 1,540,000Source | 1,578,000Source | 1,418,000Source | 919,000Source | 1,454,000Source | 1,583,000Source | 263,000Source | 2,184,000Source | 5,548,000Source | 2,503,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,851,000Source | 2,163,000Source | 1,578,000Source | 1,934,000Source | 2,233,000Source | 1,673,000Source | 2,013,000Source | 2,300,000Source | 1,764,000Source | 2,090,000Source | 2,364,000Source | 2,594,000Source |
| Other Assets, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 5,511,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 14,641,000Source | 40,509,000Source | 8,040,000Source | 16,227,000Source | 47,400,000Source | 36,319,000Source | 17,383,000Source | 44,149,000Source | 9,651,000Source | 35,566,000Source | 55,450,000Source | 84,577,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 433,787,000Source | 430,590,000Source | 465,966,000Source | 433,236,000Source | 429,659,000Source | 447,686,000Source | 432,416,000Source | 428,900,000Source | 434,474,000Source | 431,571,000Source | 428,169,000Source | 425,485,000Source |
| Retained Earnings (Accumulated Deficit)USD | -397,402,000Source | -372,102,000Source | -399,046,000Source | -388,811,000Source | -369,294,000Source | -406,443,000Source | -381,926,000Source | -354,836,000Source | -385,144,000Source | -376,535,000Source | -355,247,000Source | -422,288,000Source |
| Stockholders' Equity Attributable to ParentUSD | 36,430,000Source | 58,529,000Source | 66,930,000Source | 44,467,000Source | 60,406,000Source | 41,307,000Source | 50,532,000Source | 74,105,000Source | 49,376,000Source | 55,077,000Source | 72,962,000Source | 3,233,000Source |
| Liabilities and EquityUSD | 51,071,000Source | 99,038,000Source | 74,970,000Source | 60,694,000Source | 107,806,000Source | 77,626,000Source | 67,915,000Source | 118,254,000Source | 59,027,000Source | 90,643,000Source | 128,412,000Source | 87,810,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 8,469,000Source | 25,719,000Source | 5,825,000Source | 10,863,000Source | 25,233,000Source | 15,900,000Source | 8,957,000Source | 27,349,000Source | 5,734,000Source | 24,099,000Source | 16,303,000Source | 17,618,000Source |
| Operating Lease, Liability, CurrentUSD | 463,000Source | 389,000Source | 526,000Source | 444,000Source | 372,000Source | 504,000Source | 425,000Source | 356,000Source | 483,000Source | 407,000Source | 340,000Source | 282,000Source |
| Accounts Payable, CurrentUSD | 3,467,000Source | 4,955,000Source | 3,265,000Source | 6,172,000Source | 5,350,000Source | 5,632,000Source | 4,260,000Source | 8,918,000Source | 2,225,000Source | 4,569,000Source | 7,149,000Source | 5,937,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,821,000Source | 2,284,000Source | 1,419,000Source | 1,945,000Source | 2,388,000Source | 1,557,000Source | 2,062,000Source | 2,487,000Source | 1,692,000Source | 2,175,000Source | 2,581,000Source | 2,921,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,774,000Source | 5,508,000Source | 2,034,000Source | 2,477,000Source | 5,498,000Source | 1,529,000Source | 2,630,000Source | 4,601,000Source | 2,791,000Source | 3,793,000Source | 7,495,000Source | 5,628,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 37,900,000Source | 84,900,000Source | 71,100,000Source | 46,500,000Source | 83,700,000Source | 72,400,000Source | 53,800,000Source | 94,200,000Source | 56,300,000Source | 75,100,000Source | 98,000,000Source | 73,500,000Source |
| Deferred Revenue, CurrentUSD | 1,765,000Source | 1,642,000Source | 0Source | 1,770,000Source | 1,229,000Source | 235,000Source | 1,642,000Source | 1,083,000Source | 235,000Source | 1,642,000Source | 1,189,000Source | — |
| Deferred Revenue, NoncurrentUSD | 807,000Source | 1,294,000Source | — | 515,000Source | 1,817,000Source | — | 1,294,000Source | 2,111,000Source | 0Source | 1,294,000Source | 2,727,000Source | — |
| Short-term InvestmentsUSD | 23,131,000Source | 40,098,000Source | 43,596,000Source | 33,765,000Source | 47,044,000Source | 22,592,000Source | 33,665,000Source | 44,762,000Source | 18,772,000Source | 43,249,000Source | 40,312,000Source | 27,689,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -21,299,000Source | -5,391,000Source | -8,609,000Source | -21,288,000Source | 67,041,000Source | -62,809,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 580,000Source | 819,000Source | 2,852,000Source | 3,346,000Source | 2,624,000Source | 3,686,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | 0Source | -2,101,000Source | 1,240,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | — | — | — | 0Source | 8,849,000Source | 436,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 906,000Source | -199,000Source | -2,234,000Source | -2,650,000Source | 1,172,000Source | -1,481,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -8,101,000Source | -7,465,000Source | -5,283,000Source | -24,009,000Source | 60,159,000Source | -79,883,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -525,000Source | 12,440,000Source | 24,306,000Source | 6,150,000Source | -34,877,000Source | -27,389,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 24,038,000Source | -14,084,000Source | -14,170,000Source | -139,000Source | -36,721,000Source | 48,602,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 14,986,000Source | 29,274,000Source | 10,676,000Source | 11,264,000Source | 36,860,000Source | 7,486,000Source | 21,448,000Source | 16,595,000Source | 34,593,000Source | 46,032,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 420,000Source | 420,000Source | 840,000Source | 3,248,000Source | 5,190,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 526,000Source | 901,000Source | 568,000Source | 820,000Source | 580,000Source | 819,000Source | 2,852,000Source | 3,346,000Source | 2,624,000Source | 3,512,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | 0Source | 441,000Source | 0Source | 0Source | 0Source | 312,000Source | 312,000Source | 1,726,000Source | 2,994,000Source | 1,589,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 400,000Source | 700,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 37,900,000Source | 84,900,000Source | 71,100,000Source | 46,500,000Source | 72,400,000Source | 53,800,000Source | 56,300,000Source | 75,100,000Source | 98,000,000Source | 73,500,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 196,000Source | -154,000Source | 1,316,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -395,000Source | — | 0Source | — | 0Source | 0Source | 151,000Source | 138,000Source | -4,700,000Source |
| InterestExpenseNonoperatingUSD | — | — | 0Source | 213,000Source | 0Source | 0Source | 0Source | 173,000Source | 173,000Source | 828,000Source | — | — |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | 0Source | 14,577,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,591,000Source | -2,808,000Source | 7,397,000Source | -6,885,000Source | -21,299,000Source | -5,391,000Source | -8,609,000Source | -21,288,000Source | 67,041,000Source | -62,809,000Source |
| Nonoperating Income (Expense)USD | — | — | -186,000Source | 7,117,000Source | 15,172,000Source | 2,676,000Source | -4,360,000Source | 3,219,000Source | 7,465,000Source | 15,980,000Source | -5,490,000Source | 18,248,000Source |
| Operating ExpensesUSD | — | — | 8,739,000Source | 10,980,000Source | 8,010,000Source | 10,925,000Source | 16,939,000Source | 8,867,000Source | 36,675,000Source | 40,863,000Source | 67,472,000Source | 90,848,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 5,000Source | — | 0Source | 47,248,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 334,000Source | 660,000Source | 235,000Source | 1,364,000Source | 0Source | 257,000Source | 20,601,000Source | 3,746,000Source | 140,141,000Source | 5,091,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 3,287,000Source | 2,907,000Source | 4,119,000Source | 3,784,000Source | 4,588,000Source | 3,726,000Source | 14,395,000Source | 14,458,000Source | 20,920,000Source | 62,961,000Source |
| Operating Income (Loss)USD | — | — | -8,405,000Source | -10,320,000Source | -7,775,000Source | -9,561,000Source | -16,939,000Source | -8,610,000Source | -16,074,000Source | -37,117,000Source | 72,669,000Source | -85,757,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -8,591,000Source | -3,203,000Source | — | -6,885,000Source | — | -5,391,000Source | -8,609,000Source | -21,137,000Source | 67,179,000Source | -67,509,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | -395,000Source | — | 0Source | — | 0Source | 0Source | 151,000Source | 138,000Source | -4,700,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,591,000Source | -2,808,000Source | 7,397,000Source | -6,885,000Source | -21,299,000Source | -5,391,000Source | -8,609,000Source | -21,288,000Source | 67,041,000Source | -62,809,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | 0.63Source | -1.11Source | — | — | -0.17Source | -0.44Source | 1.4Source | -1.47Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | 0.63Source | -1.11Source | — | — | -0.17Source | -0.44Source | 1.39Source | -1.47Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 11,824,078Source | 6,218,614Source | — | — | 49,933,381Source | 48,513,073Source | 47,852,833Source | 42,613,510Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 11,824,078Source | 6,218,614Source | — | — | 49,933,381Source | 48,513,073Source | 48,390,582Source | 42,613,510Source |
| Interest Expense (non-operating)USD | — | — | 0Source | 213,000Source | 0Source | 0Source | 0Source | 173,000Source | 173,000Source | 828,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 400,000Source | 700,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 151,000Source | 138,000Source | -4,700,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | 0Source | 580,000Source | 606,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | 196,000Source | -154,000Source | 1,316,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -4,700,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 3,130,000Source | 5,198,000Source |
| Interest Income, OtherUSD | — | — | 454,000Source | 1,020,000Source | 685,000Source | 510,000Source | 535,000Source | 776,000Source | 2,177,000Source | 4,291,000Source | 3,954,000Source | 1,415,000Source |
| Nonoperating Income (Expense)USD | — | — | -186,000Source | 7,117,000Source | 15,172,000Source | 2,676,000Source | -4,360,000Source | 3,219,000Source | 7,465,000Source | 15,980,000Source | -5,490,000Source | 18,248,000Source |
| Operating ExpensesUSD | — | — | 8,739,000Source | 10,980,000Source | 8,010,000Source | 10,925,000Source | 16,939,000Source | 8,867,000Source | 36,675,000Source | 40,863,000Source | 67,472,000Source | 90,848,000Source |
| Research and Development ExpenseUSD | — | — | 5,452,000Source | 8,073,000Source | 3,891,000Source | 7,141,000Source | 12,351,000Source | 5,141,000Source | 22,280,000Source | 26,405,000Source | 30,928,000Source | 27,259,000Source |
Offerings
Registration 333-299837
Registration 333-295493
Filing attachments
scyx-ex99_1.htm · 8-K · 2026-09-28
Exhibit 99.1 SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 • BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need • Non-dilutive funding for SCY-247 enables advancement of a Phase-2 ready program, strengthening the pipeline, enhancing portfolio optionality, and bolstering the Company’s long…
Read attachment ↗scyx-ex99_1.htm · 8-K · 2026-09-22
Exhibit 99.1 SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industry JERSEY CITY, N.J., September 22, 2026 - SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to i…
Read attachment ↗scyx-ex99_1.htm · 8-K · 2026-09-10
EX-99.1 2 scyx-ex99_1.htm EX-99.1 EX-99.1 SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies. JERSEY CITY, N.J., September 10, 2026 - SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare di…
Read attachment ↗p15026909_ex99-1.htm · SCHEDULE 13G · 2026-08-12
EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗scyx-ex99_1.htm · S-8 · 2026-08-10
Exhibit 99.1 SCYNEXIS, INC. 2024 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 12, 2024 APPROVED BY THE STOCKHOLDERS: June 19, 2024 AMENDED BY THE BOARD OF DIRECTORS: April 19, 2026 ADJUSTED FOR REVERSE STOCK SPLIT: May 29, 2026 APPROVED BY THE STOCKHOLDERS: June 25, 2026 TABLE OF CONTENTS Page 1. GENERAL. 1 2. SHARES SUBJECT TO THE PLAN. 1 3. …
Read attachment ↗scyx-ex99_2.htm · S-8 · 2026-08-10
Exhibit 99.2 SCYNEXIS, INC. 2015 INDUCEMENT AWARD PLAN ADOPTED: March 26, 2015 Amended: June 9, 2019 ADJUSTED FOR REVERSE STOCK SPLIT: July 17, 2020 FURTHER AMENDED: April 30, 2021 FURTHER AMENDED: October 18, 2022 ADJUSTED FOR REVERSE STOCK SPLIT: May 29, 2026 FURTHER AMENDED: August 8, 2026 1. GENERAL. (a) Eligible Award Recipients. The persons eligible to receive Stock Awards are Eligible Employees as of the date of grant. (b) Available Awards. The Plan provides for the grant of t…
Read attachment ↗